When was Seed founded?

Seed was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Seed located?

Seed is headquartered in Los Angeles, United States.

Who is the current CEO of Seed?

Raja Dhir of Seed. They have also founded 1 company.

How many employees does Seed have?

As of May 31, 2026, the latest employee count at Seed is 3.

Is Seed a funded company?

Seed is a funded company, having raised a total of $40.6M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 06, 2018.

When was the latest funding round of Seed?

Seed's latest funding was a $***** Series A round on Apr 21, 2021, with participation from 5 investors. Its primary sector is Microbiome Therapeutics. In United States, the Microbiome Therapeutics sector has seen $104M in funding in 2026 to date.

Where does Seed rank among its competitors?

Seed ranks 15th amongst 117 active competitors, of which 29 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Nextbiotix, which secured $3.32M in Oct, 2025.

Who are the top competitors of Seed?

Seed's top competitors include Novozymes, Seres Therapeutics and Biocodex. Among them, Nextbiotix secured the most recent funding round in October, 2025.

Seed - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer synbiotics for simulating the gut microbiome. The company metabolomic sequencing and has developed a proprietary screening platform for the screening of host mechanistic pathways. The company claims that the probiotics developed to contain the strains having GRAS and/or QPS (Qualified Presumption of Safety) status. The strains have shown improvements in multiple markers of gastrointestinal health, cardiovascular health, and dermatological health.

Website: seed.com
Social
Email ID: *****@seed.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Los Angeles, United States

Stage

Series A

Total Funding

$40.6M in 3 rounds

Latest Funding Round

Series A, Apr 21, 2021, $*****

Investors

Greycroft & 28 more

Ranked

15^th among 117 active competitors

Employee Count

3 as on May 31, 2026

Investment & Acquisitions

auggi

Similar Companies

Novozymes & 149 more

View Seed's full profile

Seed has raised a total funding of $40.6M over 3 rounds. Its first funding round was on Jun 06, 2018. Its latest funding round was a Series A round on Apr 21, 2021 for $*****. 5 investors participated in its latest round. Seed has 29 institutional investors.

Here is the list of recent funding rounds of Seed:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2021	3301231	Series A	9594327	2518439	7515200	8846000
2019	1082	Series A	8655	5577	8954	Magic Hour
Jun 06, 2018	6973616	Series A	1840666	4535350	Bold Capital Partners & 7 more	9562208

Access funding benchmarks and valuations. Sign up today!

View details of Seed's funding rounds and investors

The founders of Seed is Raja Dhir. Raja Dhir is the CEO of Seed.

Here are the details of Seed's key team members:

Raja Dhir: Co-Founder & Co-CEO of Seed and founder of 1 other company.
Contact Info: 2 email addresses

View details of Seed's Founder profiles and Board Members

Seed's employee count trend

Seed has 3 employees as of May 26. Here is Seed's employee count trend over the years:

Uncover Seed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seed include Novozymes, Seres Therapeutics and Biocodex. Here is the list of Top 10 competitors of Seed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, OSTI & 3 others	73/100
2nd	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
3rd	Biocodex 1953, Gentilly (France), Unfunded	Manufactures a range of health supplements and pharmaceuticals	-	-	59/100
4th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Enterprise Ventures ... & 2 others	55/100
5th	Genome & Company 2015, Seongnam-si (South Korea), Public	Developer of microbiome-based immuno-oncology drugs	-	IMM Investment, Timefolio Capital & 8 others	55/100
6th	Resbiotic 2021, Birmingham (United States), Series A	Provider of probiotic supplements to improve health	$20.6M	Timberline, Biostack Ventures & 3 others	55/100
7th	Nextbiotix 2016, Dijon (France), Series A	Developer of probiotic for the treatment of inflammatory bowel diseases	$30.4M	Auriga Partners, Crescent Enterprises & 10 others	54/100
8th	Oragenics 1996, Tampa (United States), Public	Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health	-	Third Security, Precigen & 3 others	53/100
9th	AMILI 2019, Singapore (Singapore), Series A	Provider of gut microbiome data insights, analytics, tests, and therapeutics	$10.5M	East Ventures, Vulcan Capital & 8 others	53/100
10th	Rebiotix 2011, Roseville (United States), Acquired	Developing microbiota restoration therapy for the treatment of infectious diseases.	$29.3M	Sofia Fund, Lateral Capital & 5 others	51/100
15th	Seed 2016, Los Angeles (United States), Series A	Developer of synbiotics for simulating gut microbiome	$40.6M	Gershon Capital, Greycroft & 27 others	45/100